MX2019001421A - Composiciones de reelina para el tratamiento de trastornos neurologicos. - Google Patents
Composiciones de reelina para el tratamiento de trastornos neurologicos.Info
- Publication number
- MX2019001421A MX2019001421A MX2019001421A MX2019001421A MX2019001421A MX 2019001421 A MX2019001421 A MX 2019001421A MX 2019001421 A MX2019001421 A MX 2019001421A MX 2019001421 A MX2019001421 A MX 2019001421A MX 2019001421 A MX2019001421 A MX 2019001421A
- Authority
- MX
- Mexico
- Prior art keywords
- reelin
- syndrome
- full length
- repeat region
- repeat
- Prior art date
Links
- 102000043322 Reelin Human genes 0.000 title abstract 11
- 108700038365 Reelin Proteins 0.000 title abstract 11
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 208000025966 Neurological disease Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000003292 diminished effect Effects 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000009575 Angelman syndrome Diseases 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 208000001914 Fragile X syndrome Diseases 0.000 abstract 1
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 208000006289 Rett Syndrome Diseases 0.000 abstract 1
- 206010044688 Trisomy 21 Diseases 0.000 abstract 1
- 206010049644 Williams syndrome Diseases 0.000 abstract 1
- 230000035045 associative learning Effects 0.000 abstract 1
- 230000003920 cognitive function Effects 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 210000003520 dendritic spine Anatomy 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 230000027928 long-term synaptic potentiation Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000003961 neuronal insult Effects 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 230000003956 synaptic plasticity Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/473—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used alpha-Glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Mycology (AREA)
Abstract
Se describen cambios en los niveles de Reelina así como la señalización de Reelina después de una función cognitiva. Esto se puede llevar a cabo al administrar una cantidad terapéuticamente efectiva de un fragmento de repetición de Reelina, o una estructura formada a partir de las repeticiones del fragmento de Reelina a un paciente o sujeto. Los cambios a los niveles de Reelina se pueden utilizar para tratar diversas enfermedades neurodegenerativas, ataques neuronales o accidente cerebrovascular, tales como el síndrome X frágil, el síndrome de William, el síndrome de Rett, el síndrome de Down, el síndrome de Angelman, autismo, isquemia, hipoxia, la enfermedad de Alzheimer, y esquizofrenia. La Reelina también se puede utilizar para alterar la densidad de las espinas dendríticas, la potenciación disminuida a largo plazo, y la plasticidad sináptica disminuida y los déficits de aprendizaje asociativo. Se han encontrado particularmente útiles las estructuras formadas a partir de la región de repetición 3 de la Reelina de longitud total y la región de repetición 5 de la Reelina de longitud total, o la región de repetición 3 de la Reelina de longitud total y la región de repetición 6 de la Reelin de longitud total.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662370519P | 2016-08-03 | 2016-08-03 | |
| US201762486729P | 2017-04-18 | 2017-04-18 | |
| PCT/US2017/045307 WO2018027037A2 (en) | 2016-08-03 | 2017-08-03 | Reelin compositions for treatment of neurological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019001421A true MX2019001421A (es) | 2019-09-04 |
Family
ID=61073666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019001421A MX2019001421A (es) | 2016-08-03 | 2017-08-03 | Composiciones de reelina para el tratamiento de trastornos neurologicos. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190169246A1 (es) |
| EP (1) | EP3506927A4 (es) |
| JP (1) | JP7253800B2 (es) |
| KR (1) | KR102523237B1 (es) |
| CN (1) | CN109715194B (es) |
| AU (1) | AU2017306558B2 (es) |
| BR (1) | BR112019002204A8 (es) |
| CA (1) | CA3032697A1 (es) |
| CO (1) | CO2019001060A2 (es) |
| IL (1) | IL264603B2 (es) |
| MX (1) | MX2019001421A (es) |
| NZ (1) | NZ750291A (es) |
| WO (1) | WO2018027037A2 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230054593A1 (en) * | 2020-01-17 | 2023-02-23 | Edwin Weeber | Methods of treating fragile x syndrome with reelin |
| WO2023288325A2 (en) * | 2021-07-16 | 2023-01-19 | Ptc Therapeutics Inc. | Recombinant reelin gene therapy |
| KR20240007846A (ko) | 2022-07-08 | 2024-01-17 | 재단법인대구경북과학기술원 | Ｒｅｅｌｉｎ을 발현하는 신경세포의 대량생산방법 |
| WO2024081934A1 (en) * | 2022-10-13 | 2024-04-18 | The General Hospital Corporation | Compositions and methods using reelin in alzheimer's disease |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| US6323177B1 (en) * | 1999-06-16 | 2001-11-27 | St. Jude Children's Research Hospital | Interaction of reelin with very low density lipoprotein (VLDL) receptor for screening and therapies |
| US7510850B2 (en) * | 2005-11-10 | 2009-03-31 | Carnegie Institution Of Washington | Isolation of the mitotic spindle matrix and its methods of use |
| WO2010091399A2 (en) * | 2009-02-09 | 2010-08-12 | University Of South Florida | Reelin rescues cognitive function |
| CN104540952A (zh) * | 2012-05-18 | 2015-04-22 | 衣阿华大学研究基金会 | 用于治疗淀粉状蛋白沉积的方法和组合物 |
| CA2889990A1 (en) * | 2012-11-05 | 2014-05-08 | Genzyme Corporation | Compositions and methods for treating proteinopathies |
| EP3024497B1 (en) * | 2013-07-26 | 2021-01-13 | University of Iowa Research Foundation | Methods and compositions for treating brain diseases |
| AU2015364636B9 (en) * | 2014-12-16 | 2021-12-02 | Board Of Regents Of The University Of Nebraska | Gene therapy for Juvenile Batten Disease |
-
2017
- 2017-08-03 AU AU2017306558A patent/AU2017306558B2/en active Active
- 2017-08-03 BR BR112019002204A patent/BR112019002204A8/pt active Search and Examination
- 2017-08-03 IL IL264603A patent/IL264603B2/en unknown
- 2017-08-03 MX MX2019001421A patent/MX2019001421A/es unknown
- 2017-08-03 KR KR1020197006269A patent/KR102523237B1/ko active IP Right Grant
- 2017-08-03 CN CN201780057526.5A patent/CN109715194B/zh active Active
- 2017-08-03 WO PCT/US2017/045307 patent/WO2018027037A2/en unknown
- 2017-08-03 EP EP17837688.5A patent/EP3506927A4/en active Pending
- 2017-08-03 JP JP2019505258A patent/JP7253800B2/ja active Active
- 2017-08-03 CA CA3032697A patent/CA3032697A1/en active Pending
- 2017-08-03 NZ NZ750291A patent/NZ750291A/en unknown
-
2019
- 2019-02-01 CO CONC2019/0001060A patent/CO2019001060A2/es unknown
- 2019-02-01 US US16/264,896 patent/US20190169246A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20190169246A1 (en) | 2019-06-06 |
| JP2019524775A (ja) | 2019-09-05 |
| WO2018027037A2 (en) | 2018-02-08 |
| NZ750291A (en) | 2021-07-30 |
| IL264603B2 (en) | 2023-10-01 |
| EP3506927A2 (en) | 2019-07-10 |
| IL264603A (en) | 2019-02-28 |
| CO2019001060A2 (es) | 2019-02-19 |
| CA3032697A1 (en) | 2018-02-08 |
| AU2017306558B2 (en) | 2024-09-19 |
| IL264603B1 (en) | 2023-06-01 |
| KR102523237B1 (ko) | 2023-04-18 |
| EP3506927A4 (en) | 2020-05-06 |
| JP7253800B2 (ja) | 2023-04-07 |
| CN109715194A (zh) | 2019-05-03 |
| CN109715194B (zh) | 2024-06-11 |
| BR112019002204A2 (pt) | 2019-07-09 |
| WO2018027037A3 (en) | 2018-03-01 |
| BR112019002204A8 (pt) | 2019-10-01 |
| AU2017306558A1 (en) | 2019-02-21 |
| KR20190035842A (ko) | 2019-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019004616A (es) | Métodos de uso de indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de wnt/b-catenina. | |
| DOP2019000187A (es) | Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo | |
| MX2019001421A (es) | Composiciones de reelina para el tratamiento de trastornos neurologicos. | |
| PH12018500087A1 (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors | |
| CY1120369T1 (el) | Θεραπεια νευρολογικων διαταραχων βασει βακλοφαινης και ακαμπροσατης | |
| EA201991375A1 (ru) | Бицикло[1.1.1]пентановые ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания | |
| CY1116699T1 (el) | Παραγωγα αλφα-αμινοαμιδιου τα οποια ειναι χρησιμα στην αγωγη γνωστικων διαταραχων | |
| EA201071243A1 (ru) | Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом | |
| WO2018060732A3 (en) | Compositions and methods for treating seizure disorders | |
| PH12016501600A1 (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
| EA201400969A1 (ru) | Новые терапевтические подходы для лечения болезни паркинсона | |
| EA201990400A1 (ru) | Соединения и композиции и их применение | |
| UY37466A (es) | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa | |
| EA201990450A1 (ru) | Ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания | |
| EA202091020A1 (ru) | Замещенные имидазопиридинамиды и их применение | |
| EA201691602A1 (ru) | Комбинация баклофена, акампросата и среднецепочечных триглицеридов для лечения неврологических расстройств | |
| EA201492102A1 (ru) | Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны | |
| AR112472A1 (es) | Forma de sales cristalinas de amida de levodopa y métodos para elaborarlas y usarlas | |
| PH12020551300A1 (en) | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof | |
| MX2023014484A (es) | Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion. | |
| BR112015015509A2 (pt) | composto farmacêutico para a prevenção e tratamento de uma doença ou desordem cognitiva, neuro degenerativa ou doença neuronal | |
| CY1124821T1 (el) | Ιγμεσινη για χρηση στη θεραπεια της νοσου του αλτσχαιμερ | |
| MX2021007142A (es) | Compuestos organicos. | |
| CY1116158T1 (el) | Υποκατεστημενα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3 |